Skip to main content
. 2019 May 8;17:89. doi: 10.1186/s12916-019-1323-8

Fig. 1.

Fig. 1

SWOT analysis (strengths, weaknesses, opportunities and threats) summarizing the promising features and potential drawbacks of vedolizumab trough level monitoring in inflammatory bowel disease (IBD). PK/PD: pharmacokinetic/pharmacodynamic; TDM: therapeutic drug monitoring